Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics reports a robust first half of 2024 with total revenues surging to $12.1 million, marking a more than threefold increase from the previous year, primarily fueled by a 161% rise in ACCRUFeR® prescription sales and a significant 33% jump in net average sales price. Despite increased operating losses due to U.S. market expansion, the company remains optimistic about its growth trajectory and financial health, bolstered by a recent $5.7 million financing agreement. Shield’s momentum is expected to continue with further commercial and developmental progress in both the U.S. and international markets.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
